News | Blood Testing | April 28, 2017

New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors

Prevencio’s multi-protein HART CVE test superior to clinical risk assessments and TMAO test

New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors

April 28, 2017 — Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than evaluating commonly-used risk factors in determining whether a person will have a heart attack, stroke or major cardiac event. Researchers believe the data, published in the American Journal of Cardiology (AJC), could revolutionize how doctors identify patients — not only higher-risk patients who need aggressive treatment, but also lower-risk patients who could avoid expensive and invasive procedures.

In the study, researchers tested patients’ blood for more than 100 proteins at Myriad RBM. They then developed and validated a multi-protein blood test, HART CVE, to predict a patient’s one-year risk of having a heart attack, stroke or cardiovascular death.

Principal investigator James L. Januzzi, M.D., a practicing cardiologist at Massachusetts General Hospital and professor of medicine at Harvard Medical School, led a team of researchers who tested more than 900 subjects for the occurrence of a heart attack, stroke or cardiovascular death within one year. When the test score was divided into low-risk and high-risk categories, the test was 97 percent accurate (negative predictive value) at determining a low-risk patient would not have a heart attack or major cardiac event within one year.

“This new risk score test provides improved accuracy as compared to clinical risk factors and could be particularly useful for those patients with suspected or known stable heart disease, for which there are very few prognostic risk models,” said Januzzi. “In addition to leading to more appropriate care of patients, it could also have a role in ‘enriching’ pharmaceutical cardiac clinical trials, which could lead to lower trial costs and reduced time to complete clinical trials.”

The new blood test also outperforms other clinical risk assessments such as the Euro Heart Score and the TMAO test, which uses a metabolite found in the intestine and has been associated with major cardiovascular events. The test could also be used to aid scientific research in the future, helping to identify higher-risk patients for pharmaceutical trials and potentially saving millions of dollars in trial costs.

Cardiovascular disease is the leading cause of death in the United States. According to the American Heart Association, the U.S. spends approximately $316 billion annually on cardiovascular disease and stroke, or approximately 10 percent of the total healthcare budget. Spending is expected to jump to $918 billion annually by 2030, with more than 40 percent of adults having CV disease.

In addition to the HART CVE test, Prevencio is developing HART CAD, a blood test for diagnosing coronary artery obstruction that is more accurate than standard exercise or stress tests. The company is also looking to expand beyond HART CVE and HART CAD tests.

The HART CVE and HART CAD tests will potentially be available to medical professionals for use by 2018; Prevencio is in discussion with multiple potential partners.

For more information: www.prevenciomed.com

Related Content

More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
Overlay Init